Abstract: A semiconductor optical device has a semiconductor substrate, and an active layer which is formed above the semiconductor substrate, the active layer having a plurality of quantum wells formed from a plurality of barrier layers and a plurality of well layers sandwiched among the plurality of barrier layers. At least one well layer of the plurality of well layers is formed from an InxaGa(1-xa)As film, and a composition ratio xa of the In takes any one value within a range from approximately 0.05 to approximately 0.20. Accordingly, the semiconductor optical device is formed as a strained well layer in which lattice distortion bought about in the well layer takes any one value within a range from approximately 0.35% to approximately 1.5%, and the strained well layer is formed so as to have a bandgap wavelength different from those of the other well layers.

Abstract: 4-amino-5-oxy-2,6,6-tri methyl-2-cycloheptene compounds represented by the following general formula: ##STR1## (wherein R.sup.1 and R.sup.2 each independently represent a hydrogen atom, an alkyl group which may have a substituent, or a phenyl group which may have a hydroxyl group, lower alkoxy group, amino group, nitro group, carboxyl group, lower alkoxycarbonyl group or halogen atom, or R.sup.1, R.sup.2 and the nitrogen atom together represent a saturated nitrogen heterocyclic group; R.sup.3 represents a hydrogen atom, a lower alkyl group or a lower aliphatic acyl group); and W represents an oxo group, oxime group or oxime ether group; and their pharmacologically acceptable salts and solvates.The 4-amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds exhibit an effect against rat peripheral arterial occlusion models, spontaneous hypertensive rats and histamine-induced airway contraction models, and are thus useful as remedy for hypertension, peripheral arterial occlusion and bronchial asthma.

Abstract: A phosphorescent article having a first transparent resin layer, a phosphorescent layer, and a second transparent resin layer sequentially superposed in the order mentioned on a supporting layer possessed of a reflective surface. The phosphorescent layer is coated in a tightly sealed state with the first and second transparent resin layers. Preferably the second transparent resin layer has a projecting part so formed as to protrude from the surface of the part thereof which covers the phosphorescent layer, namely in the part which corresponds to the underlying phosphorescent layer, and a surface layer (printed layer) is printed or applied on the part of the surface other than the projecting part, namely on the surface of the part in which the phosphorescent layer does not exist. SrAl.sub.2 O.sub.4 is used as a phosphorescent pigment to be contained in the phosphorescent layer and a transparent resin containing no ultraviolet absorbent is used for the first and second transparent resin layers.

Abstract: A Saishin N derivative represented by the following general formula: ##STR1## wherein X represents a carbonyl group or a >CH--ORx group, or X bonds to a carbon atom in Y or Z to represent a >C(ORx)--O-- group; Y and Z may be the same or different and each represents a carbonyl group or a >CH--ORy group, or each bonds to an oxygen atom in X to represent a >CH-- group; the broken line represents an optional bond; and Rx and Ry may be the same or different and each represents a hydrogen atom or an alkyl, alkenyl, aralkenyl, aralkyl, heterocyclic-alkyl or acyl group, is provided which is therapeutically usable as an antiulcer agent.

Abstract: There are provided 4,5-Dihydroxy-2,6,6-trimethyl-2-cyclohepten-1-one, a method for preparing the same and an antiulcer agent containing the same as an effective ingredient.

Abstract: Imidazo[4,5-b]pyridine compounds of the general formula [I] are provided: ##STR1## where R.sup.1 is straight-chain or branched C.sub.1-8 alkoxy which may be substituted with cycloalkyl, or C.sub.2-4 fluoroalkyloxy, R.sup.2 is H, methyl or methoxy, and R.sup.3 and R.sup.4 are each H or methyl and may be the same or different. All these compounds have good activity of inhibiting potassium ion-dependent adenosine triphosphatase and excellent storage stability, so that they are usable for the treatment of gastric and/or duodenal ulcers.

Abstract: Benzimidazole derivatives of the general formula [I] are provided: ##STR1## wherein R.sup.1 is hydrogen, methyl or methoxy, and R.sup.2 and R.sup.3 each is hydrogen or methyl, at least one of R.sup.1, R.sup.2 and R.sup.3 being a member other than hydrogen. The benzimidazole derivatives exhibit an excellent activity of inhibiting the potassium ion-dependent adenosine triphosphatase, as well as a good stability during storage. Therefore, the benzimidazole derivatives are usable for the treatment of gastric and/or duodenal ulcers.